The six-month TRAILHEAD data shows encouraging consistency across multiple measures in a difficult-to-treat adult DMD population. The key catalyst to watch is BASECAMP enrollment completion and initial data, expected to begin in Q3 2026. Traders should monitor for pediatric proof-of-concept data, which would be more impactful given greater remaining muscle mass.
Price Chart
Executive Summary
Satellos reported six-month interim data from the TRAILHEAD Phase 2 study of SAT-3247 in adults with Duchenne muscular dystrophy, showing reduced muscle fat fraction (mean -3.7%), increased upper limb effort (~34% improvement), stable strength, and a 38% decline in CK. The safety profile remained favorable with no serious TEAEs. The data is early (n=4) and open-label, but the consistency across multiple measures is encouraging for the ongoing BASECAMP pediatric study.
Key Facts
- Six-month interim data from TRAILHEAD (n=4 adults with DMD) showed mean muscle fat fraction decline of 3.7% (49.7% to 46.0%) on MRI.
- Mean TE99C upper limb effort improved ~34% from 16.1 to 21.6 joules/kg.
- Mean CK declined 38% from baseline (2130 u/l to 1315 u/l) through month 6.
- No serious TEAEs, no discontinuations, 100% compliance over ~186 days.
- Company on track to complete BASECAMP enrollment and initiate US TRAILHEAD sites in Q3 2026.
Financial Impact
No financial data in release; market cap ~$171M. Positive interim data could drive re-rating if BASECAMP replicates results in larger pediatric population.
Risk Factors
- Very small sample size (n=4) limits statistical reliability and generalizability.
- Open-label design with no placebo control introduces potential for bias.
- Adult DMD population has advanced muscle loss; results may not translate to pediatric BASECAMP study.
- No financial data or guidance provided; stock may be volatile on sentiment alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3323924 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | — | $6.54 (+1.87%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | — | $6.54 (−2.39%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | — | $6.54 (−18.76%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | — | $6.54 (−23.06%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | — | $6.54 (−23.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.54 (−24.91%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.54 (−24.91%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.54 (−30.13%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.54 (−34.73%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.54 (−27.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers